Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Patients must have a history of histologically or cytologically confirmed stage I, II, or III breast cancer that have received 2 cycles of paclitaxel, and expected to receive paclitaxel for two more cycles, and are experiencing grade 1 peripheral neuropathy (CTCAE criteria)~* Performance ECOG 0-2 (Karnofsky Performance Status \>= 60%)~* Life expectancy of greater than 6 months~* Ability to understand and the willingness to sign a written informed consent document~Exclusion~* Patients with radiologically confirmed stage IV breast cancer~* Patients who had acupuncture in the previous 8 weeks~* Change in use of any of the following drugs in the prior 4 weeks: opiates, antidepressants, or anxiolytics (change is defined as initiation or cessation of treatment, or change in prescribed dose or regimen)~* Patients with needle phobia~* Patients who experienced any peripheral neuropathy prior to chemotherapy~* Patients who have the potential for serious bleeding due to inherited diseases such as hemophilia~* Patients with diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
- Arm II (Type: EXPERIMENTAL): Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).